These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9501886)

  • 1. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study.
    Buitelaar JK; van der Gaag RJ; van der Hoeven J
    J Clin Psychiatry; 1998 Feb; 59(2):56-9. PubMed ID: 9501886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
    Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
    J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological management in children and adolescents with pervasive developmental disorder.
    Sung M; Fung DS; Cai Y; Ooi YP
    Aust N Z J Psychiatry; 2010 May; 44(5):410-28. PubMed ID: 20047454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders.
    Hardan AY; Jou RJ; Handen BL
    J Child Adolesc Psychopharmacol; 2004; 14(3):426-32. PubMed ID: 15650499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR; DuPont RL; Hedges D; Haskins JT
    J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.
    Miyaoka T; Wake R; Furuya M; Liaury K; Ieda M; Kawakami K; Tsuchie K; Inagaki T; Horiguchi J
    BMC Psychiatry; 2012 Nov; 12():215. PubMed ID: 23194148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism.
    Ghanizadeh A; Ayoobzadehshirazi A
    Pediatr Neurol; 2015 Jan; 52(1):77-81. PubMed ID: 25451017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.
    Ishitobi M; Hiratani M; Kosaka H; Takahashi T; Mizuno T; Asano M; Murata T; Tomoda A; Wada Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):128-31. PubMed ID: 22245026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.
    Ceranoglu TA; Wozniak J; Fried R; Galdo M; Hoskova B; DeLeon Fong M; Biederman J; Joshi G
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):28-33. PubMed ID: 30452283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
    Sukhodolsky DG; Scahill L; Gadow KD; Arnold LE; Aman MG; McDougle CJ; McCracken JT; Tierney E; Williams White S; Lecavalier L; Vitiello B
    J Abnorm Child Psychol; 2008 Jan; 36(1):117-28. PubMed ID: 17674186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders.
    Jou RJ; Handen BL; Hardan AY
    J Child Adolesc Psychopharmacol; 2005 Apr; 15(2):325-30. PubMed ID: 15910217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presentation of anxiety in children with pervasive developmental disorders.
    Weisbrot DM; Gadow KD; DeVincent CJ; Pomeroy J
    J Child Adolesc Psychopharmacol; 2005 Jun; 15(3):477-96. PubMed ID: 16092912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.
    Erickson CA; Veenstra-Vanderweele JM; Melmed RD; McCracken JT; Ginsberg LD; Sikich L; Scahill L; Cherubini M; Zarevics P; Walton-Bowen K; Carpenter RL; Bear MF; Wang PP; King BH
    J Autism Dev Disord; 2014 Apr; 44(4):958-64. PubMed ID: 24272415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole for autism spectrum disorders (ASD).
    Ching H; Pringsheim T
    Cochrane Database Syst Rev; 2012 May; (5):CD009043. PubMed ID: 22592735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone for bruxism in a child with pervasive developmental disorder-not otherwise specified.
    Orsagh-Yentis DK; Wink LK; Stigler KA; Erickson CA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):643-5. PubMed ID: 22136097
    [No Abstract]   [Full Text] [Related]  

  • 20. Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression.
    Pfeffer CR; Jiang H; Domeshek LJ
    J Child Adolesc Psychopharmacol; 1997; 7(3):145-55. PubMed ID: 9466232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.